Abacavir dose adjustments in patients with hepatic impairment

Abstract: 1630

Please be aware of this information, but at this time the Benet group is not recommending Abacavir dose adjustments.

Take home message: ABC dose reduction appears necessary in pts with hepatic impairment with Child Pugh scores > 5-6.

Citation: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 2000, page 331

Pharmacokinetics of, and Tolerability to, a Single, Oral, 600mg Dose of Abacavir in HIV-Positive Subjects with or without Liver Disease.

Abacavir, a synthetic carbocyclic nucleoside analog with specific anti HIV activity, is extensively metabolized by the liver. Primary pathway for metabolism in man is by alcohol-aldehyde dehydrogenase and by glucuronidation to produce the 5-carboxylate (2269W93) and the 5-glucuronide (361W94) metabolites. Because changes in the metabolism due to hepatic insufficiency could potentially be of clinical significance, a study was designed to evaluate the kinetics of, and tolerability to, a single, oral, 600mg dose of abacavir in HIV+ subjects with or without liver disease. Pharmacokinetic (PK) parameters of abacavir and its two major metabolites were determined in 9 HIV+ subjects with clinically diagnosed moderate cirrhosis and 9 normal controls, matched for sex, age and weight. PK analyses were performed using model-independent methods and statistical analysis of primary PK parameters was performed by analysis of variance. All adverse events (AEs) were recorded throughout the study. Results: All patients in the moderate cirrhosis group had Child-Pugh scores of 5-6 (mild impairment). Results showed that the PK profile of abacavir was altered in subjects with cirrhosis. There were concomitant increases in AUC¥ and t1/2 of abacavir, 89% and 58% respectively, and a 47% decrease in CL/F of abacavir in the cirrhosis group compared with the control group (p<0.01). Furthermore, there were marked increases in t1/2 of 2269W93 (31%; p<0.05) and in t1/2 of 361W94 (21%) but no statistically significant differences for AUC¥ of the metabolites. No previously unknown AEs related to abacavir were observed during this study. Conclusion: The changes in abacavir kinetics suggest that abacavir daily dose should be reduced to 150mg BID in patients with mild hepatic impairment with cirrhosis.

Key Words
Abacavir
Human pharmacokinetics
Liver

F. Raffi, Y. Benhamou, D. Sereni, T. Poynard, C. Brunet-Francois, A. Emmanuel, C. Gillotin, S. Fosse, G. Yuen

1 Hopital Hotel-Dieu, Nantes, France; 2 Hopital Pitie-Salpetriere, Paris, France; 3 Hopital Saint-Louis, Paris, France; 4 Glaxo Wellcome, Marly le Roi, France; 5 Glaxo Wellcome Inc., Res. Triangle Park, NC